Cambridge Investment Research Advisors
SBIO icon

Cambridge Investment Research Advisors’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

Cambridge Investment Research Advisors’s Portfolio SBIO Stock Details SBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$567K Buy
+8,774
New +$481K ﹤0.01% 2846
2023
Q4 		– Sell
-8,923
Closed -$243K – 3289
2023
Q3 		$243K Sell
8,923
-146
-2% -$4.4K ﹤0.01% 2666
2023
Q2 		$286K Buy
9,069
+382
+4% +$11.9K ﹤0.01% 2567
2023
Q1 		$236K Sell
8,687
-1,381
-14% -$41.7K ﹤0.01% 2683
2022
Q4 		$306K Sell
10,068
-1,137
-10% -$34.2K ﹤0.01% 2418
2022
Q3 		$338K Sell
11,205
-172
-2% -$5.43K ﹤0.01% 2269
2022
Q2 		$315K Sell
11,377
-410
-3% -$11.7K ﹤0.01% 2340
2022
Q1 		$397K Buy
11,787
+778
+7% +$27K ﹤0.01% 2299
2021
Q4 		$465K Sell
11,009
-6,827
-38% -$304K ﹤0.01% 2161
2021
Q3 		$812K Sell
17,836
-231
-1% -$10.6K ﹤0.01% 1693
2021
Q2 		$884K Buy
18,067
+1,383
+8% +$66.3K ﹤0.01% 1619
2021
Q1 		$839K Buy
16,684
+5,963
+56% +$330K ﹤0.01% 1555
2020
Q4 		$549K Buy
+10,721
New +$510K ﹤0.01% 1710
2016
Q1 		– Sell
-7,792
Closed -$247K – 1651
2015
Q4 		$247K Sell
7,792
-459
-6% -$14.1K 0.01% 1229
2015
Q3 		$230K Buy
+8,251
New +$288K 0.01% 1176

Other funds holding SBIO

GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $599M AUM 28.66% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
MIG
McGuire Investment Group Wakefield, Rhode Island $1.14B AUM 79.59% 1-Year Est. Return
IFG
Independent Financial Group San Diego, California $5.35B AUM 43.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return

Cambridge Investment Research Advisors's SBIO Position: Q2 2026 in Review

Cambridge Investment Research Advisors opened a new position in ALPS Medical Breakthroughs ETF (SBIO) in Q2 2026: 8,774 shares worth $567K. The stake represents ﹤0.01% of the portfolio and ranks #2846 among its holdings. This is a return to the name: Cambridge Investment Research Advisors previously reported a position in SBIO as recently as Q3 2023.

Cambridge Investment Research Advisors first reported a position in SBIO in Q3 2015 and has held it in 15 quarters since. The position peaked at $884K in Q2 2021. 21 funds tracked by Wall St. Rank hold SBIO as of Q2 2026.

  • Cambridge Investment Research Advisors held 8,774 shares of ALPS Medical Breakthroughs ETF worth $567K as of Q2 2026.
  • ALPS Medical Breakthroughs ETF was a new Cambridge Investment Research Advisors position in Q2 2026.
  • ALPS Medical Breakthroughs ETF made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #2846 holding.
  • Cambridge Investment Research Advisors first reported a position in ALPS Medical Breakthroughs ETF in Q3 2015 and has held it in 15 quarters since.
  • Cambridge Investment Research Advisors's ALPS Medical Breakthroughs ETF position peaked at $884K in Q2 2021.
  • 21 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.